JMPWA
PCRX icon

JP Morgan Private Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$343K Buy
11,185
+590
+6% +$21.3K ﹤0.01% 1406
2023
Q2 		$425K Sell
10,595
-11,323
-52% -$468K ﹤0.01% 1101
2023
Q1 		$894K Buy
21,918
+6,033
+38% +$240K ﹤0.01% 1209
2022
Q4 		$613K Sell
15,885
-7,554
-32% -$368K ﹤0.01% 1382
2022
Q3 		$1.25M Buy
23,439
+3,595
+18% +$200K ﹤0.01% 1038
2022
Q2 		$1.16M Sell
19,844
-4,703
-19% -$308K ﹤0.01% 1065
2022
Q1 		$1.87M Sell
24,547
-14,854
-38% -$990K ﹤0.01% 927
2021
Q4 		$2.37M Buy
39,401
+4,584
+13% +$253K 0.01% 839
2021
Q3 		$1.95M Buy
34,817
+149
+0.4% +$8.59K ﹤0.01% 914
2021
Q2 		$2.1M Buy
34,668
+16,097
+87% +$1.02M 0.01% 855
2021
Q1 		$1.3M Sell
18,571
-15,776
-46% -$1.13M ﹤0.01% 923
2020
Q4 		$2.06M Buy
34,347
+17,072
+99% +$1,000K 0.01% 719
2020
Q3 		$1.04M Buy
17,275
+2,443
+16% +$142K ﹤0.01% 875
2020
Q2 		$778K Buy
14,832
+5,801
+64% +$242K ﹤0.01% 898
2020
Q1 		$303K Buy
9,031
+1,289
+17% +$53.5K ﹤0.01% 1135
2019
Q4 		$351K Sell
7,742
-615
-7% -$26.1K ﹤0.01% 1172
2019
Q3 		$318K Buy
8,357
+2,438
+41% +$97.3K ﹤0.01% 1168
2019
Q2 		$257K Sell
5,919
-1,094
-16% -$46.4K ﹤0.01% 1208
2019
Q1 		$267K Sell
7,013
-467
-6% -$18.2K ﹤0.01% 1266
2018
Q4 		$322K Buy
7,480
+2,236
+43% +$104K ﹤0.01% 1137
2018
Q3 		$258K Buy
+5,244
New +$227K ﹤0.01% 1376
2018
Q1 		– Sell
-4,394
Closed -$201K – 1356
2017
Q4 		$201K Buy
+4,394
New +$174K ﹤0.01% 1189
2015
Q2 		– Sell
-2,560
Closed -$227K – 1118
2015
Q1 		$227K Hold
2,560
– – ﹤0.01% 992
2014
Q4 		$227K Hold
2,560
– – ﹤0.01% 956
2014
Q3 		$248K Hold
2,560
– – ﹤0.01% 904
2014
Q2 		$235K Buy
+2,560
New +$195K ﹤0.01% 769

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

JP Morgan Private Wealth Advisors's PCRX Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors increased its Pacira BioSciences (PCRX) stake by 5.6% in Q3 2023, buying an estimated $21.3K and bringing the position to 11,185 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1406.

JP Morgan Private Wealth Advisors first reported a position in PCRX in Q2 2014 and has held it in 26 quarters since. The position peaked at $2.37M in Q4 2021. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 11,185 shares of Pacira BioSciences worth $343K as of Q3 2023.
  • JP Morgan Private Wealth Advisors bought 590 Pacira BioSciences shares in Q3 2023, an estimated $21.3K.
  • Pacira BioSciences made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1406 holding.
  • JP Morgan Private Wealth Advisors first reported a position in Pacira BioSciences in Q2 2014 and has held it in 26 quarters since.
  • JP Morgan Private Wealth Advisors's Pacira BioSciences position peaked at $2.37M in Q4 2021.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.